LTLeila Taj

Leila Taj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Leila Taj has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Expression of mir-221, mir-29a, mir-155 and mir-146a in Peripheral Blood Mononuclear Cell (PBMC) in HIV-1 Infected Patients

    by Arsalan Narouei, Negin Hosseini Rouzbahani, Maryam Ghanbari, Leila Taj, Minoo Mohraz, Mohammad Gholami, Kazem Baesi

    Background and Aim: patients infected by HIV-1, some cellular biomarkers such as microRNAs have an important function in the suppression or progression of the disease. The aim of the current study is to evaluate the expression of mir-221, mir-29a, mir-155, and mir-146a in HIV-1 infected patients. Methods: The miRNAs of 60 HIV-1 infected patients (sample group) and 20 healthy controls (normal group) were extracted from their peripheral mononuclear cells. We used TaqMan-based Real-- time PCR for evaluation of expression mir-155, mir-221, mir-29a and mir-146a by the comparative method. To evaluate differences among the data, one-way ANOVA was used. The expression of mir-155 and mir-146a in HIV-1 patients (sample group) was down-regulated in comparison with healthy controls (normal group) with a confidence value (***p<0.001). In addition, in the sample group, the expression of mir-221 was downregulated compared to the normal group (***p<.001). Results: There was no significant difference in expression mi-29a in the sample and control group. In the sample group, mir-221 had a low expression, and mir-29a had a high expression, respectively. According to the results of the current study and comparative studies, it seems that the microRNA has an important role in the progression or suppression of HIV-1 infection. Conclusion: However, the data showed that besides other cellular and viral factor, these miRNAs could be used as a biomarker. However, the miRNAs field experts are in general agreement that more investigation is needed to use miRNAs as a biomarker in HIV.


  • Epidemiology of HIV in Iran

    by Zeinab Najafi, Leila Taj, Omid Dadras, Fatemeh Ghadimi, Banafsheh Moradmand, SeyedAhmad SeyedAlinaghi

    Iran has been one the active countries fighting against HIV/AIDS in Middle East during last decades. Moreover, there is a strong push to strengthen the national health management system concerning HIV prevention and control. In Iran, HIV disease has its own unique features, from changes in modes of transmission to improvement in prevention programs, which can make it a good case for closer scrutiny. The present review describes the HIV epidemic in Iran from the first case diagnosed till recent progresses in diagnosis, treatment, and prevention among different groups at risk. Not only we addressed the key populations and community-based attempts to overcome HIV-related issues in clinics, but we also elaborated on the efforts and trends in society and the actual behaviors related to HIV/AIDS. Being located in the Middle East and North Africa (MENA) region, given the country-specific characteristics, despite all the national efforts along with other countries in this region, Iran still needs to take extra measures to reduce HIV transmission, especially in health education. Although Iran is one of the pioneers in implementing pertinent policies in the MENA region, including harm reduction services to reduce HIV incidence, people with substance use disorder continue to be the majority of those living with HIV in the country. Similar to other countries in this region, the HIV prevention and control programs aim at 90-90-90 targets to eliminate HIV infection and reduce the transmission, especially the mother-to-child transmission and among other key populations.